1. Scrip
  2. >>Business

Strides' New CEO Reiterates Strategy, Thrust On Execution

Q3 Revenues Up 29% Led By US, UK

 
• By Vibha Ravi

Newly-appointed CEO at Strides, R Ananthanarayanan, sees no reason to change course as current strategy continues yielding positive results. Company posts 29% increase in third-quarter revenues on the back of 62% growth in the US

Business success growing growth increase up concept. Wooded cube block on white background with word GROWTH
Strides Pharma Posts Impressive Growth • Source: Shutterstock

A new CEO is often under close observation for indications of a shift in strategic direction. At Strides Pharma Science Ltd, earlier known as Strides Shasun Ltd., R Ananthanarayanan, appointed CEO a little over a fortnight ago, doesn’t see reason to rock the boat, at least for now.

On a 30 January investor call detailing third-quarter results for FY20, as former CEO and current chairman Arun Kumar introduced Ananthanarayanan, the latter signaled an intent to focus on execution rather than a reset. Strides had announced his appointment on 9 January

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Finance Watch: Funding Alternatives Become The Norm In Tough Public Markets

 
• By Mandy Jackson

Public Company Edition: With fewer follow-on offerings, drug developers are pursuing other options. Axsome accessed up to $570m in debt, Evolus obtained $250m in a new credit facility and Abeona raised $155m from a PRV sale, but Apimeds was able to execute a small $13.5m IPO.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

More from Scrip

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.